As of Mar 22
| -0.0284 / -3.97%|
The 1 analysts offering 12-month price forecasts for Peregrine Pharmaceuticals Inc have a median target of 1.50, with a high estimate of 1.50 and a low estimate of 1.50. The median estimate represents a +118.12% increase from the last price of 0.69.
The current consensus among 1 polled investment analysts is to Buy stock in Peregrine Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.